The cost of drugs has remained a popular media topic for several years. For the past 3 years, annual expenditures on drugs represented 10% of total health care costs. 1, 2 Total drug costs in the United States were 5.8% higher in 2016 compared with 2015. 3 Factors that influence drug expenditures include cost and utilization. Guideline changes and new uses for a drug can increase utilization. New generics and competition within a branded drug class can decrease unit cost, while supply issues can increase costs. 3 Utilization went up by only 1%, suggesting the primary reason for the increase in drug expenditures is due to higher acquisition cost. From 2011 to 2015, branded drugs represented 71% to 74% of annual expenditures, even as the number of branded prescriptions decreased 20% from 2011 to 2015. So despite 83% of prescriptions being for generic drugs, only 11% of the cost for drugs in 2015 was due to generics. The third piece of the drug cost puzzle is branded generics, which represented only 5% of prescriptions in 2015, but 16% of costs. So while utilization of branded generics is low, they do contribute to the increase in costs. 4 A key driver of the increase in the cost of branded drugs is specialty medications. Specialty medications are drugs that are high cost, usually a biologic and/or require special monitoring. The drugs may be given orally or by injection. It has been estimated that 70% of the increase in drug costs from 2010 to 2015 was due to specialty medications. In 2015, specialty medications represented 36% of total drugs costs, up from 24% in 2010. 4 In cases of managed care prescriptions, a new drug may be placed on a higher tier. Pharmaceutical manufacturers have sought to make it easier for patients to obtain the drug by provision coupons, vouchers, and discount cards to reduce copays. This ends up being more expensive for the drug budget, because a higher cost drug replaces a preferred lower cost alternative. So knowledge of when new drugs are coming and their potential formulary status can help predict when copay reduction programs may be put in place. 5 Because drug expenses represent a significant part of health care costs, it is a strategic necessity to monitor the pharmaceutical pipeline. Knowledge of when new drug classes are coming or new products to compete with established products is needed to plan a discussion on the drug's formulary status and to be able to develop special procedures for monitoring or liming availability. An expensive injectable biologic that requires special monitoring and is only available through a limited distribution network will not only impact a pharmacy's drug budget but also personnel to procure the drug and manage it. By knowing whether other drugs in the same class or more convenient administration may become available in the near future, a plan can be developed to meet the needs for a patient population. Justifications can be developed to implement incremental value-based formulary decisions 6 and restricted access, or to plan for valuebased negotiations for the new drug. 7 The need to monitor the pharmaceutical pipeline can be seen in the topics inclusion in national meetings and publications. The annual drug expenditures report by American Society of Health-System Pharmacists (ASHP; Rx Forecast) regularly includes a section of new drugs projected to be approved in the next year. The Academy of Managed Care Pharmacy meetings include multiple presentations on the pharmaceutical pipeline. Presentations are divided into conventional drugs, specialty medications, and even separate high-cost therapeutic areas such as oncology.
Various methods to monitor the pharmaceutical pipeline have been used over the years. Simple lists and spreadsheets provide some basic information. Some very in-depth and costly services are also available that provide analyses by health care professionals, researchers, and lawyers of a drug's potential impact. Hospital Pharmacy carries wellwritten and researched reviews of new drugs from the Formulary Monograph Service in each issue. Beginning in June 2017, I started providing a brief review of a drug class or therapeutic class in Hospital Pharmacy. Using information from the Prescribe Right database, each review gives a snapshot of a group of potential new drugs in late stages of development. The reviews are designed to keep you informed about drugs in development that you will be discussing.
